HCPCS Code Applications and Approvals: July 2023
Quarterly archive · CMS Level II HCPCS59 coding decisions from the First Quarter 2023 CMS cycle
These are the Centers for Medicare and Medicaid Services (CMS) Level II HCPCS drug coding decisions from the First Quarter 2023 coding cycle, which took effect July 1, 2023.
For the newest decisions, see the current HCPCS code applications and approvals.
CMS Level II HCPCS Drug Coding Decisions
Does not include Q4 skin repair and wound codes.
How to Read This Table
- Action
- CMS decision on the application — establish a new code, revise an existing descriptor, reinstate a code, or discontinue one. See the glossary.
- Code Change
- Where CMS retires a code in favor of another, the new code shows the code it replaces and the retired code shows its replacement.
- 505(b)(2) and Biosimilar
- Tags beside the drug name mark products approved under the FDA 505(b)(2) pathway and biosimilars.
- Effective
- First date of service on which the code may be billed. Codes effective before this quarter reflect retroactive establishment; codes effective after it are decisions CMS scheduled for a later quarter.
July 2023
| HCPCS | Drug & Descriptor | Company | Code Change | Action | Effective |
|---|---|---|---|---|---|
| J0137 | Acetaminophen (Hikma) Injection, acetaminophen (hikma) not therapeutically equivalent to j0131, 10 mg | — | — | Establish | |
| J0206 | Allopurinol Sodium 505(b)(2) Injection, allopurinol sodium, 1 mg | — | — | Establish | |
| J0216 | Alfentanil Hydrochloride 505(b)(2) Injection, alfentanil hydrochloride, 500 micrograms | — | — | Establish | |
| J0457 | Aztreonam 505(b)(2) Injection, aztreonam, 100 mg | — | — | Establish | |
| J0665 | Bupivicaine 505(b)(2) Injection, bupivicaine, not otherwise specified, 0.5 mg | — | — | Establish | |
| J0736 | Clindamycin Phosphate 505(b)(2) Injection, clindamycin phosphate, 300 mg | — | — | Establish | |
| J0737 | Clindamycin Phosphate (Baxter) Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | — | — | Establish | |
| J1411 | HEMGENIX Injection, etranacogene dezaparvovec-drlb, per therapeutic dose | CSL Behring, LLC Intravenous | — | Establish | |
| J1440 | REBYOTA Fecal microbiota, live - jslm, 1 ml | — | — | Establish | |
| J1576 | Immune Globulin (Panzyga) 505(b)(2) Injection, immune globulin (panzyga), intravenous, non- lyophilized (e.g., liquid), 500 mg | — | — | Establish | |
| J1805 | Esmolol Hydrochloride 505(b)(2) Injection, esmolol hydrochloride, 10 mg | — | — | Establish | |
| J1806 | Esmolol Hydrochloride (Wg Critical Care) 505(b)(2) Injection, esmolol hydrochloride (wg critical care) not therapeutically equivalent to j1805, 10 mg | — | — | Establish | |
| J1811 | Insulin (Fiasp) 505(b)(2) Insulin (fiasp) for administration through dme (i.e., insulin pump) per 50 units | — | — | Establish | |
| J1812 | Insulin (Fiasp) 505(b)(2) Insulin (fiasp), per 5 units | — | — | Establish | |
| J1813 | Insulin (Lyumjev) 505(b)(2) Insulin (lyumjev) for administration through dme (i.e., insulin pump) per 50 units | — | — | Establish | |
| J1814 | Insulin (Lyumjev) 505(b)(2) Insulin (lyumjev), per 5 units | — | — | Establish | |
| J1836 | Metronidazole 505(b)(2) Injection, metronidazole, 10 mg | — | — | Establish | |
| J1920 | Labetalol Hydrochloride 505(b)(2) Injection, labetalol hydrochloride, 5 mg | — | — | Establish | |
| J1921 | Labetalol Hydrochloride (Hikma) Injection, labetalol hydrochloride (hikma) not therapeutically equivalent to j1920, 5 mg | — | — | Establish | |
| J1941 | Furosemide (Furoscix) Injection, furosemide (furoscix), 20 mg | — | — | Establish | |
| J1961 | SUNLENCA Injection, lenacapavir, 1 mg | Gilead Sciences Subcutaneous | — | Establish | |
| J2249 | BYFAVO Injection, remimazolam, 1 mg | Eagle Pharmaceuticals, Inc. Intravenous | — | Establish | |
| J2305 | Nitroglycerin 505(b)(2) Injection, nitroglycerin, 5 mg | — | — | Establish | |
| J2329 | Briumvi Injection, ublituximab-xiiy, 1mg | TG Therapeutics Intravenous | — | Establish | |
| J2370 | Phenylephrine Hcl Injection, phenylephrine hcl, up to 1 ml | — | — | Discontinue | |
| J2371 | Phenylephrine Hydrochloride 505(b)(2) Injection, phenylephrine hydrochloride, 20 micrograms | — | — | Establish | |
| J2372 | Phenylephrine Hydrochloride (Biorphen) Injection, phenylephrine hydrochloride (biorphen), 20 micrograms | — | — | Establish | |
| J2426 | Paliperidone Palmitate Extended Release (Invega Sustenna) 505(b)(2) Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | — | — | Revise | |
| J2427 | Paliperidone Palmitate Extended Release (Invega Hafyera, or Invega Trinza) Injection, paliperidone palmitate extended release (invega hafyera, or invega trinza), 1 mg | — | — | Establish | |
| J2561 | Sezaby 505(b)(2) Injection, phenobarbital sodium (sezaby), 1 mg | Sun Pharmaceutical Industries Ltd. (Sun Pharma) Intravenous | — | Establish | |
| J2598 | Vasopressin 505(b)(2) Injection, vasopressin, 1 unit | — | — | Establish | |
| J2599 | Vasopressin (American Regent) 505(b)(2) Injection, vasopressin (american regent) not therapeutically equivalent to j2598, 1 unit | — | — | Establish | |
| J2806 | Sincalide Injection 505(b)(2) Injection, sincalide (maia) not therapeutically equivalent to j2805, 5 micrograms | Maia Pharmaceuticals, Inc. | — | Establish | |
| J7213 | Coagulation Factor Ix (Recombinant) 505(b)(2) Injection, coagulation factor ix (recombinant), ixinity, 1 i.u. | — | — | Establish | |
| J9029 | ADSTILADRIN Injection, nadofaragene firadenovec-vncg, per therapeutic dose | Ferring Pharmaceuticals, Inc. Intravesical | — | Establish | |
| J9056 | VIVIMUSTA 505(b)(2) Injection, bendamustine hydrochloride (vivimusta), 1 mg | Slayback Pharma, LLC. Intravenous | — | Establish | |
| J9058 | Bendamustine Hydrochloride 505(b)(2) Injection, bendamustine hydrochloride (apotex), 1 mg | Apotex Corp. Intravenous | — | Establish | |
| J9059 | Baxter's Bendamustine Hydrochloride Injection 505(b)(2) Injection, bendamustine hydrochloride (baxter), 1 mg | Baxter Healthcare Corporation Intravenous | — | Establish | |
| J9063 | ELAHERE Injection, mirvetuximab soravtansine-gynx, 1 mg | ImmunoGen Inc. Intravenous | — | Establish | |
| J9259 | Paclitaxel Protein-Bound Particles 505(b)(2) Injection, paclitaxel protein-bound particles (american regent) not therapeutically equivalent to j9264, 1 mg | American Regent, Inc. Intravenous | — | Establish | |
| J9322 | Pemetrexed (Bluepoint) 505(b)(2) Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg | — | — | Establish | |
| J9323 | Pemetrexed 505(b)(2) Injection, pemetrexed ditromethamine, 10 mg | Pfizer, Inc. Intravenous | — | Establish | |
| J9347 | IMJUDO Injection, tremelimumab-actl, 1 mg | AstraZeneca Pharmaceuticals LP Intravenous | — | Establish | |
| J9350 | LUNSUMIO Injection, mosunetuzumab-axgb, 1 mg | Genentech Intravenous | — | Establish | |
| J9380 | TECVAYLI Injection, teclistamab-cqyv, 0.5 mg | Johnson & Johnson Health Subcutaneous | — | Establish | |
| J9381 | TZIELD Injection, teplizumab-mzwv, 5 mcg | Provention Bio, Inc. | — | Establish | |
| Q4272 | Esano A Esano a, per square centimeter | Evolution Biologyx, LLC | — | Establish | |
| Q4273 | Esano AAA Esano aaa, per square centimeter | Evolution Biologyx, LLC | — | Establish | |
| Q4274 | Esano AC Esano ac, per square centimeter | Evolution Biologyx, LLC | — | Establish | |
| Q4275 | Esano ACA Esano aca, per square centimeter | Evolution Biologyx, LLC | — | Establish | |
| Q4276 | ORION Amniotic Membrane Orion, per square centimeter | Legacy Medical Consultant, LLC | — | Establish | |
| Q4277 | WoundPlus Membrane Woundplus membrane or e-graft, per square centimeter | Skye Biologics | — | Establish | |
| Q4278 | EPIEFFECT Epieffect, per square centimeter | MiMedx Group, Inc. | — | Establish | |
| Q4280 | Xcell Amnio Matrix Xcell amnio matrix, per square centimeter | Precise Bioscience | — | Establish | |
| Q4281 | Barrera SL/Barrera DL Barrera sl or barrera dl, per square centimeter | RegenTx Partners | — | Establish | |
| Q4282 | CYGNUS Dual Cygnus dual, per square centimeter | VIVEX Biologics | — | Establish | |
| Q4283 | Biovance 3L Biovance tri-layer or biovance 3l, per square centimeter | RMBB Health | — | Establish | |
| Q4284 | DermaBind SL Dermabind sl, per square centimeter | HealthTech Wound Care | — | Establish | |
| Q5131 | IDACIO Biosimilar Injection, adalimumab-aacf (idacio), biosimilar, 20 mg | Fresenius Kabi Subcutaneous | — | Establish |
No coding decisions match those filters.
Source: CMS HCPCS application summaries, First Quarter 2023 coding cycle (PDF) . Data current as of October 7, 2026.
Other Quarters
Decisions per quarter since July 2022 · select a bar to open that quarter
